Imago BioSciences, Inc., a San Francisco, CA-based biotech company developing innovative therapeutics, raised $26.5m in Series A financing.
The round was led by Clarus Ventures with participation from Frazier Healthcare, Amgen Ventures, and Merck Research Labs Venture Fund. Representatives from Clarus Ventures and Frazier Healthcare will join the company’s board of directors.
Proceeds will be used to advance the research and clinical development program of therapeutics that alter gene expression patterns.
Led by Hugh Young Rienhoff, M.D., CEO, Imago BioSciences is a clinical development company dedicated to orphan diseases that involve genetic alterations disturbing normal patterns of gene expression, or diseases in which modifying gene expression patterns can have a therapeutic effect.